Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 258-263

  Yellen, Paige ^a,b   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Akt; ERK; Fatty acid synthase; K Ras

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; FATTY ACID SYNTHASE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; BENZAMIDE DERIVATIVE; CERULENIN; CHROMONE DERIVATIVE; DIPHENYLAMINE; DRUG DERIVATIVE; FATTY ACID SYNTHASE INHIBITOR; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MORPHOLINE DERIVATIVE; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY ACID SYNTHESIS; GENE MUTATION; HUMAN; HUMAN CELL; LIPOGENESIS; ONCOGENE K RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AKT; DRUG ANTAGONISM; ERK; GENE SILENCING; GENETICS; K-RAS; METABOLISM; TUMOR CELL LINE;

AKT; ERK; FATTY ACID SYNTHASE; K-RAS;

BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERULENIN; CHROMONES; DIPHENYLAMINE; ENZYME ACTIVATION; FATTY ACID SYNTHASES; FATTY ACID SYNTHESIS INHIBITORS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPOGENESIS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS;

EID: 84908672508     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.027     Document Type: Article

References (44)

1. Brusselmans K., De Schrijver E., Verhoeven G., Swinnen J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005, 65:6719-6725.
2. Calvisi D.F., Wang C., Ho C., Ladu S., Lee S.A., Mattu S., et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011, 140:1071-1083.
3. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
4. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl Acad. Sci. U.S.A. 1994, 91:6379-6383.
5. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000, 60:213-218.
6. Swinnen J.V., Vanderhoydonc F., Elgamal A.A., Eelen M., Vercaeren I., Joniau S., et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int. J. Cancer 2000, 88:176-179.
7. Guo D., Prins R.M., Dang J., Kuga D., Iwanami A., Soto H., et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal 2009, 2:ra82.
8. Van de Sande T., Roskams T., Lerut E., Joniau S., Van Poppel H., Verhoeven G., et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J. Pathol 2005, 206:214-219.
9. Wang H.Q., Altomare D.A., Skele K.L., Poulikakos P.I., Kuhajda F.P., Di Cristofano A., et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005, 24:3574-3582.
10. Porstmann T., Griffiths B., Chung Y.L., Delpuech O., Griffiths J.R., Downward J., et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005, 24:6465-6481.
11. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
12. Plas D.R., Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24:7435-7442.
13. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
14. Vogt P.K., Kang S., Elsliger M.A., Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci 2007, 32:342-349.
15. Bandyopadhyay S., Pai S.K., Watabe M., Gross S.C., Hirota S., Hosobe S., et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 2005, 24:5389-5395.
16. Zhu X., Qin X., Fei M., Hou W., Greshock J., Bachman K.E., et al. Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma. Int. J. Mol. Sci 2012, 13:9980-9991.
17. Hao J., Zhu L., Zhao S., Liu S., Liu Q., Duan H. PTEN ameliorates high glucose-induced lipid deposits through regulating SREBP-1/FASN/ACC pathway in renal proximal tubular cells. Exp. Cell Res 2011, 317:1629-1639.
18. Castellano E., Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011, 2:261-274.
19. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
20. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., et al. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
21. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
22. Baines A.T., Xu D., Der C.J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem 2011, 3:1787-1808.
23. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest 2011, 121:4311-4321.
24. Kalaany N.Y., Sabatini D.M. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009, 458:725-731.
25. Halilovic E., She Q.B., Ye Q., Pagliarini R., Sellers W.R., Solit D.B., et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010, 70:6804-6814.
26. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
27. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med 2008, 14:1351-1356.
28. Yellen P., Saqcena M., Salloum D., Feng J., Preda A., Xu L., et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011, 10:3948-3956.
29. Kamphorst J.J., Cross J.R., Fan J., de Stanchina E., Mathew R., White E.P., et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. U.S.A. 2013, 110:8882-8887.
30. Salloum D., Mukhopadhyay S., Tung K., Polonetskaya A., Foster D.A. Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol. Cancer Ther 2014, 13:733-741.
31. D'Agnolo G., Rosenfeld I.S., Awaya J., Omura S., Vagelos P.R. Inhibition of fatty acid synthesis by the antibiotic cerulenin. Specific inactivation of beta-ketoacyl-acyl carrier protein synthetase. Biochim. Biophys. Acta 1973, 326:155-156.
32. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
33. Jeng H.H., Taylor L.J., Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun 2012, 3:1168.
34. Roberts P.J., Usary J.E., Darr D.B., Dillon P.M., Pfefferle A.D., Whittle M.C., et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res 2012, 18:5290-5303.
35. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
36. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65:7052-7058.
37. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
38. Brink M., Weijenberg M.P., De Goeij A.F., Schouten L.J., Koedijk F.D., Roemen G.M., et al. Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2004, 25:1619-1628.
39. Yabushita S., Fukamachi K., Tanaka H., Fukuda T., Sumida K., Deguchi Y., et al. Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Carcinogenesis 2013, 34:1251-1259.
40. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
41. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D.W., Smith L.S., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res 2012, 18:2316-2325.
42. Bar-Sagi D., Feramisco J.R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 1986, 233:1061-1068.
43. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
44. Girard J., Ferre P., Foufelle F. Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu. Rev. Nutr 1997, 17:325-352.